Summary

Executive Summary

The Global Rheumatoid Arthritis Market was valued at USD 24.46 Billion in the year 2020. Globally, the market for rheumatoid arthritis is increasing rapidly and the major factor that drives the growth of rheumatoid arthritis is the increasing ageing population. Furthermore, some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis.

DMARDs segment is expected to hold a significant share in the Rheumatoid Arthritis Market on the back of the increasing prevalence of rheumatoid arthritis incidences across the globe, the launch of the therapeutic agents, and the favourable reimbursement policies for the high-cost treatment products. These are the major factors propelling the growth of the market.

Americas region dominated the global Rheumatoid Arthritis market and led the industry in 2020 owing to the presence of a large patient base and availability of well-developed infrastructure, rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment.

There is also an increase in funds provided to academic research institutions and individual researchers that is expected to boost the market growth. Moreover, various initiatives by international bodies, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular diseases, Rheumatoid Arthritis and cancer are anticipated to facilitate the growth of the market.

Scope of the Report

• The report presents the analysis of the Rheumatoid Arthritis market for the historical period of 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Rheumatoid Arthritis Market by Value (USD Million).

• The report analyses the Rheumatoid Arthritis Market By Drug Type – NSAID(non-steroidal anti-inflammatory drugs), DMARDs (Disease-modifying anti-rheumatic drug), Corticosteroids, Others

• The report analyses the Rheumatoid Arthritis Market by Treatment – Tendon Repair, Joint Fusion, Joint Replacement, Others.

• The report analyses the Rheumatoid Arthritis Market By Diagnosis – CRP (Creative Protein Test), ESR (Erythrocyte Sedimentation Rate), Others.

• The Global Rheumatoid Arthritis Market has been analysed by countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

• Also, the attractiveness of the market has been presented by region, by Drug Type, by Treatment, By Diagnosis.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Merck KGaA, Sanofi, Eli Lilly Company, Amgen Inc., Bristol-Mayor Squibb, F. Hoffman-La Roche Ltd., Johnson & Johnson, Cipla, Pfizer, Galapagos NV, Gilead Sciences.

Key Target Audience

• Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities

ページTOPに戻る

Table of Contents

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Rheumatoid Arthritis Market: Product Outlook

4. Global Rheumatoid Arthritis Market: Sizing and Forecast

4.1 Global Rheumatoid Arthritis Market Size, By Value, 2016-2026

4.2 Impact of COVID-19 on Global Rheumatoid Arthritis Market

5. Global Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis

5.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Drug Type

5.1.1 NSAID(non-steroidal anti-inflammatory drugs) - Market Size and Forecast (2016-2026)

5.1.2 DMARD'S(Disease-modifying anti-rheumatic drug) - Market Size and Forecast (2016-2026)

5.1.3 Corticosteroids- Market Size and Forecast (2016-2026)

5.1.4 Others - Market Size and Forecast (2016-2026)

5.2 Competitive Scenario of Global Rheumatoid Arthritis Market: By Treatment

5.2.1 Tendon Repair - Market Size and Forecast (2016-2026)

5.2.2 Joint Fusion- Market Size and Forecast (2016-2026)

5.2.3 Joint Replacement- Market Size and Forecast (2016-2026)

5.2.4 Others - Market Size and Forecast (2016-2026)

5.3 Competitive Scenario of Global Rheumatoid Arthritis Market: By Diagnosis

5.3.1 CRP(Creative Protein Test) - Market Size and Forecast (2016-2026)

5.3.2 ESR (Erythrocyte Sedimentation Rate)- Market Size and Forecast (2016-2026)

5.3.3 Others - Market Size and Forecast (2016-2026)

6. Global Rheumatoid Arthritis Market: Regional Analysis

6.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Region

7. Americas Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)

7.1 Americas Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

7.2 Americas Rheumatoid Arthritis Market - Prominent Companies

7.3 Market Segmentation By Drug Type (DMARDís, NSAID, Corticosteroids and Others)

7.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)

7.5 Market Segmentation By Diagnosis (CRP, ESR and Others)

7.6 Americas Rheumatoid Arthritis Market: Country Analysis

7.7 Market Opportunity Chart of Americas Rheumatoid Arthritis Market - By Country, By Value, 2026

7.8 Competitive Scenario of Americas Rheumatoid Arthritis Market: By Country

7.9 United States Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

7.10 United States Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

7.11 Canada Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

7.12 Canada Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8. Europe Rheumatoid Arthritis Market: An Analysis (2016-2026)

8.1 Europe Rheumatoid Arthritis Market: Size and Forecast (2016-2026)

8.2 Europe Rheumatoid Arthritis Market - Prominent Companies

8.3 Market Segmentation By Drug Type (DMARDís, NSAID, Corticosteroids and Others)

8.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)

8.5 Market Segmentation By Diagnosis (CRP, ESR and Others)

8.6 Europe Rheumatoid Arthritis Market: Country Analysis

8.7 Market Opportunity Chart of Europe Rheumatoid Arthritis Market - By Country, By Value, 2026

8.8 Competitive Scenario of Europe Rheumatoid Arthritis Market: By Country

8.9 Germany Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.10 Germany Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.11 United Kingdom Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.12 United Kingdom Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.13 France Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.14 France Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.15 Italy Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.16 Italy Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8.17 Spain Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

8.18 Spain Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

9. Asia Pacific Rheumatoid Arthritis Market: An Analysis (2016-2026)

9.1 Asia Pacific Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.2 Asia Pacific Rheumatoid Arthritis Market - Prominent Companies

9.3 Market Segmentation By Drug Type (DMARDs, NSAID, Corticosteroids and Others)

9.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)

9.5 Market Segmentation By Diagnosis (CRP, ESR and Others)

9.6 Asia Pacific Rheumatoid Arthritis Market: Country Analysis

9.7 Market Opportunity Chart of Asia Pacific Rheumatoid Arthritis Market - By Country, By Value, 2026

9.8 Competitive Scenario of Asia Pacific Rheumatoid Arthritis Market: By Country

9.9 China Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.10 China Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

9.11 Japan Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.12 Japan Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

9.13 India Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value

9.14 India Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

10. Global Rheumatoid Arthritis Market Dynamics

10.1 Drivers

10.2 Restraints

10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Drug Type, 2026

11.2 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Treatment, 2026

11.3 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Diagnosis, 2026

11.4 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Region, 2026

12. Competitive Landscape

12.1 Product Pipeline of Leading Rheumatoid Arthritis Companies

12.2 Market Share Analysis

13. Company Analysis

13.1 Merck KGaA

13.2 Sanofi

13.3 Eli Lilly Company

13.4 Amgen Inc.

13.5 Bristol-Mayor Squibb

13.6 F. Hoffman-La Roche Ltd

13.7 Johnson & Johnson

13.8 Cipla

13.9 Pfizer

13.10 Galapagos NV

13.11 Gilead Sciences